TICKERNERD
Menu
ARQTARQTHealthcare · Biotechnology

ARQT Stock Forecast: Arcutis Biotherapeutics, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$24
+2.18% on the day

The 8 Wall Street analysts covering Arcutis Biotherapeutics, Inc. hold a median 12-month price target of $37 — +54.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 88 of 100 as at 10 Sept 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$3.0B
Ticker Nerd rank
88 / 100
Median analyst target
$37
Analysts covering
8
Revenue$129.9M+59.3% y/y
Operating income$16.4M
Net income$15.0M
Free cash flow$12.5M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+1.0%
1M
−8.9%
YTD
−17.7%
1Y
+35.0%
From 52W high
−23.4%
From 52W low
+42.8%
$17
$31
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ARQT stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Arcutis Biotherapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 10 Sept 2026
88 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
96
Quality
95
Revisions
91
Growth
79
Momentum
75
Volatility
74
Size
31
Accruals
27
Issuance
26

Value (96): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Issuance (26): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ARQT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ARQT, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$15$20$25$30$35$40Oct 25Jan 26Apr 26Jul 26ARQTHigh $40Median $37Low $34

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says8 analysts
7 Buy1 Hold0 Sell
Low $34Median $37High $40

The green dot is the last close — the median target sits +54.9% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 3 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
6 Aug 2026GuggenheimMaintainsBuy$35 → $38
6 Aug 2026Morgan StanleyMaintainsOverweight$34 → $38
6 Aug 2026NeedhamMaintainsBuy$36 → $40
7 May 2026NeedhamReiteratesBuy$36
7 May 2026NeedhamReiteratesBuy—
2 Mar 2026MizuhoMaintainsOutperform—
27 Feb 2026GuggenheimMaintainsBuy—
26 Feb 2026HC Wainwright & Co.MaintainsBuy—
26 Feb 2026NeedhamMaintainsBuy—
26 Feb 2026TD CowenMaintainsBuy—
26 Jan 2026NeedhamMaintainsBuy—
28 Nov 2025MizuhoMaintainsOutperform—
30 Oct 2025Goldman SachsMaintainsNeutral—
28 Oct 2025NeedhamMaintainsBuy—
7 Aug 2025NeedhamMaintainsBuy—
25 July 2025Goldman SachsInitiatesNeutral—
23 May 2025NeedhamReiteratesBuy—
9 Apr 2025NeedhamReiteratesBuy—
3 Apr 2025GuggenheimReiteratesBuy—
3 Apr 2025HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ARQT appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

ARQT vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Arcutis Biotherapeutics, Inc. returned +35.0% against +17.5% for the S&P 500, dividends included.

ARQT vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140160180Oct 25Jan 26Apr 26Jul 26ARQTS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ARQT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+149.5%
Analysts raising
4
Analysts cutting
0
Fundamentals

Arcutis Biotherapeutics, Inc. (ARQT) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
108.6×

Cheaper than 6% of US stocks

Price / sales
6.5×

Cheaper than 20% of US stocks

Price / book
13.6×

Cheaper than 7% of US stocks

EV / EBITDA
77.1×

Cheaper than 3% of US stocks

Growth & margins
Revenue growth (YoY)
59.3%

Higher than 88% of US stocks

Earnings growth (YoY)
59.3%

Higher than 77% of US stocks

Gross margin
91.6%

Higher than 97% of US stocks

Operating margin
12.7%

Higher than 69% of US stocks

Net margin
6.1%

Higher than 63% of US stocks

Returns & dividend
Return on equity
15.9%

Higher than 76% of US stocks

Return on assets
5.1%

Higher than 77% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Arcutis Biotherapeutics, Inc. (ARQT) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Arcutis Biotherapeutics, Inc. has a market value of $3.0B and an enterprise value of $2.8B.

  • Revenue in the twelve months to 30 June 2026: $464.0M. The latest quarter grew 59.3% year on year.

  • Net income over the same four quarters: $28.5M, a 6.1% net margin.

  • Diluted earnings per share, trailing twelve months: $0.21.

  • Free cash flow in the twelve months to 30 June 2026: $39.2M.

  • Shares outstanding: 125.6M.

  • Trailing P/E: 108.6×; forward P/E: 18.3× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Arcutis Biotherapeutics, Inc. employs 354 people — $1.3M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 12 Sept 2026

Data provided by Twelve Data

Peers

ARQT vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ARQTArcutis Biotherapeutics, Inc.$3.0B
88
MBXMBX Biosciences, Inc.$2.9B
38
CLDXCelldex Therapeutics, Inc.$2.9B
30
QUREUniQure NV$3.0B
57
IRONDisc Medicine, Inc.$2.8B
38
IMNMImmunome, Inc.$2.8B
34
SLSSELLAS Life Sciences Group, Inc.$2.7B
61

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Arcutis Biotherapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ARQT news & analysis

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire · 4 Sept 2026neutral

Arcutis Biotherapeutics announced the grant of 57,000 restricted stock units (RSUs) of common stock to 11 newly hired employees. The awards were approved by the Compensation Committee under the company's 2022 Inducement Plan, with a grant date of September 1, 2026, as a material inducement for the employees' commencement of employment, in accordance with Nasdaq Listing Rule 5635(c)(4).

Why it matters — This information matters to ARQT watchers as it reflects routine equity compensation activity tied to new employee hiring, disclosed to comply with Nasdaq listing rules.

Arcutis Management to Present at the Morgan Stanley 24th Annual Global Healthcare Conference

GlobeNewsWire · 2 Sept 2026neutral

Arcutis Biotherapeutics announced that its management will present at the Morgan Stanley 24th Annual Global Healthcare Conference, to be held September 14-16, 2026, in New York. The company is a commercial-stage biopharmaceutical firm focused on immuno-dermatology innovations.

Why it matters — The presentation gives Arcutis management an opportunity to address investors and industry attendees at a major healthcare investment conference.

Here's Why You Should Add ARQT Stock to Your Portfolio Now

Zacks Investment Research · 28 Aug 2026positive

Arcutis Biotherapeutics raised its 2026 revenue guidance as its product Zoryve gains momentum. The company is also expanding into younger patients and advancing potential new indications.

Why it matters — ARQT watchers would care because the raised 2026 guidance signals growing commercial traction for Zoryve and potential expansion into new patient groups and indications.

Zacks Industry Outlook Halozyme, Repligen, Iovance, Arcutis and Precigen

Zacks Investment Research · 27 Aug 2026neutral

Zacks Investment Research published an Industry Outlook article that highlights Halozyme, Repligen, Iovance, Arcutis and Precigen. Arcutis Biotherapeutics is among the companies featured in this industry-level analysis.

Why it matters — ARQT watchers would care because the company's inclusion in a Zacks industry outlook signals it is being tracked within its sector alongside comparable peers.

5 Biotech Stocks Worth Adding to Your Portfolio Now

Zacks Investment Research · 26 Aug 2026positive

A Zacks Investment Research article highlights ARQT as one of five biotech stocks worth adding to a portfolio, citing new drug approvals and encouraging pipeline progress in the Zacks Biomedical and Genetics industry. The report notes that a strong portfolio and solid pipeline progress position ARQT well despite macroeconomic uncertainty.

Why it matters — For ARQT watchers, being named alongside peers as a stock worth adding signals confidence in the company's drug pipeline and its positioning within the sector.

FAQ

Frequently asked questions about ARQT stock

What is the ARQT stock price forecast for 2026-2027?

The 8 Wall Street analysts covering Arcutis Biotherapeutics, Inc. have a median 12-month price target of $37, with estimates ranging from $34 to $40. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ARQT stock a buy right now?

Of the 8 analysts covering Arcutis Biotherapeutics, Inc., 7 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Arcutis Biotherapeutics, Inc. 88 out of 100 across roughly 4,600 US stocks as at 10 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ARQT?

As at 10 Sept 2026, Arcutis Biotherapeutics, Inc. ranks 88 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (96 of 100).

Will ARQT stock go up?

No one can know that. What the data says: the median 12-month target from 8 analysts implies +54.9% from the last close, and Ticker Nerd's factor model ranks Arcutis Biotherapeutics, Inc. 88 out of 100 as at 10 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ARQT stock forecast for 2030?

No analyst covering Arcutis Biotherapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ARQT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $34 to $40 over the next 12 months.

How has ARQT stock performed over the past year?

Arcutis Biotherapeutics, Inc. returned +35.0% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Arcutis Biotherapeutics, Inc. do?

Arcutis Biotherapeutics, Inc. is a commercial-stage medical dermatology company focused on developing and commercializing therapies for immune-mediated skin diseases.

What is the latest news on ARQT?

The most recent item we track (GlobeNewsWire, 4 Sept 2026): "Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)". Arcutis Biotherapeutics announced the grant of 57,000 restricted stock units (RSUs) of common stock to 11 newly hired employees. The awards were approved by the Compensation Committee under the company's 2022 Inducement Plan, with a grant date of September 1, 2026, as a material inducement for the employees' commencement of employment, in accordance with Nasdaq Listing Rule 5635(c)(4).

Company

About Arcutis Biotherapeutics, Inc.

Arcutis Biotherapeutics, Inc. is a commercial-stage medical dermatology company focused on developing and commercializing therapies for immune-mediated skin diseases. The company’s portfolio centers on ZORYVE, a branded treatment platform that includes topical formulations used in conditions such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis, and psoriasis in sensitive areas. Arcutis also advances a pipeline of dermatology candidates, including additional topical and systemic programs designed to address inflammatory skin disorders with high unmet medical need. Its research and development approach combines dermatology expertise with targeted drug development against biologically validated pathways, positioning the company as a specialist player in the medical dermatology market. Based in Westlake Village, California, Arcutis Biotherapeutics serves patients, dermatology clinicians, and healthcare providers through prescription therapies aimed at chronic skin conditions.

CEO Mr. Todd Franklin Watanabe M.A. · 354 employees · United States · https://www.arcutis.com